Trial
NCT04285268
Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Rutgers, The State University of New Jersey
Collaborators
National Cancer Institute (NCI)
Condition
High Grade B-Cell Lymphoma, Not Otherwise Specified
Intervention
Bortezomib
Why stopped
This study was never submitted to the IRB for review and approval.
No research subjects were enrolled.
.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-30